Article Search

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810

March 1, 2024

Adjuvant therapy with pazopanib after metastesectomy for met-ccRCC did not show a meaningful benefit. It seems that the current standard is for adjuvant pembro after metastesectomy within a year of nephrectomy.

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

July 1, 2023

Atezo and cabo is a NO.

Article Search
Article Search Form
Cancer Types
Filter by Cancer Types
Month Contributed
Show FCS Articles Only
Sort Order
Sort Order Field
Number of Posts

Article Archive (2021)

About This Site

FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.

Article Search

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

Keyword Search

Article Search

Cancer Types

Month Contributed

Show FCS Articles Only

Sort Order

Number of Posts

Menu

About This Site